|Day's Range||54.06 - 54.06|
|52 Week Range||52.68 - 68.67|
|PE Ratio (TTM)||166.34|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Shire to announce second quarter 2017 results Dublin, Ireland - July 18, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), will announce second quarter 2017 earnings on Thursday August 3, 2017. Results press ...
Shire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific Antibody Shire obtains worldwide license to pursue development and commercialization of a novel, ...
The chief executive of Shire has questioned investors' valuation of his company, arguing the potential of a number of promising drugs has yet to be factored into its share price. Flemming Ornskov also ...